Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
As of close of business last night, Processa Pharmaceuticals Inc’s stock clocked out at $2.88, down -1.71% from its previous closing price of $2.93. In other words, the price has decreased by -$1.71 from its previous closing price. On the day, 0.13 million shares were traded. PCSA stock price reached its highest trading level at $2.9987 during the session, while it also had its lowest trading level at $2.83.
Ratios:
To gain a deeper understanding of PCSA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.76 and its Current Ratio is at 3.76. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
. In the most recent recommendation for this company, H.C. Wainwright on April 25, 2024, initiated with a Buy rating and assigned the stock a target price of $8.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 27 ’25 when Yorke Justin W bought 12,400 shares for $0.80 per share. The transaction valued at 9,889 led to the insider holds 12,400 shares of the business.
Ng George K bought 87,200 shares of PCSA for $69,542 on Jan 27 ’25. The Chief Executive Officer now owns 87,200 shares after completing the transaction at $0.80 per share. On Jan 27 ’25, another insider, Young David, who serves as the Pres. Research & Development of the company, bought 124,500 shares for $0.80 each. As a result, the insider paid 99,289 and bolstered with 205,405 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PCSA now has a Market Capitalization of 6525412 and an Enterprise Value of 216994.
Stock Price History:
The Beta on a monthly basis for PCSA is 1.10, which has changed by -0.8697778 over the last 52 weeks, in comparison to a change of 0.17511821 over the same period for the S&P500. Over the past 52 weeks, PCSA has reached a high of $27.00, while it has fallen to a 52-week low of $2.74. The 50-Day Moving Average of the stock is -56.18%, while the 200-Day Moving Average is calculated to be -55.71%.
Shares Statistics:
It appears that PCSA traded 1.09M shares on average per day over the past three months and 4510926 shares per day over the past ten days. A total of 2.11M shares are outstanding, with a floating share count of 2.00M. Insiders hold about 11.62% of the company’s shares, while institutions hold 3.14% stake in the company. Shares short for PCSA as of 1765756800 were 138188 with a Short Ratio of 0.13, compared to 1763078400 on 214301. Therefore, it implies a Short% of Shares Outstanding of 138188 and a Short% of Float of 6.16.
Earnings Estimates
The stock of Processa Pharmaceuticals Inc (PCSA) is currently being evaluated by 1.0 analysts who are actively contributing to its market rating. Analysts are recommending an EPS of between -$10.75 and -$10.75 for the fiscal current year, implying an average EPS of -$10.75. EPS for the following year is -$3.75, with 1.0 analysts recommending between -$3.75 and -$3.75.
